Quick Answer
Olema Pharmaceuticals, Inc. reported Diluted EPS of $1.87 per share (loss) for fiscal year 2025.
Olema Pharmaceuticals, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.87 | +15.0% |
| 2024 | -$2.20 | -2.8% |
| 2023 | -$2.14 | +18.3% |
| 2022 | -$2.62 | -45.6% |
| 2021 | -$1.80 | +47.4% |
| 2020 | -$3.42 | -106.0% |
| 2019 | -$1.66 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.49 | +18.3% | +3.9% |
| June 30, 2025 | -$0.51 | +5.6% | -41.7% |
| March 31, 2025 | -$0.36 | +35.7% | +40.0% |
| September 30, 2024 | -$0.60 | -25.0% | -11.1% |
| June 30, 2024 | -$0.54 | -10.2% | +3.6% |
| March 31, 2024 | -$0.56 | +20.0% | -16.7% |
| September 30, 2023 | -$0.48 | +15.8% | +2.0% |
| June 30, 2023 | -$0.49 | +40.2% | +30.0% |
- Olema Pharmaceuticals, Inc. showed an increase of +15.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, Olema Pharmaceuticals, Inc.’s diluted eps has declined by 12.7% (from $1.66 per share (loss) to $1.87 per share (loss)).
- The most recent figure is from Olema Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: